Drug Profile

Research programme: stem cell therapies - Cellaion

Alternative Names: H2Stem

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Promethera Biosciences
Developer Cellaion
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Alpha 1-antitrypsin deficiency; Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

28 Sep 2024 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Belgium
28 Nov 2020 No recent reports of development identified for research development in Fibrosis in Belgium
28 Nov 2020 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in Belgium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com